Aberdeen Group plc Trims Stock Position in Rallybio Corporation $RLYB

Aberdeen Group plc lessened its position in shares of Rallybio Corporation (NASDAQ:RLYB) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,595,262 shares of the company’s stock after selling 131,805 shares during the quarter. Aberdeen Group plc owned about 3.83% of Rallybio worth $539,000 at the end of the most recent reporting period.

Rallybio Price Performance

NASDAQ RLYB opened at $0.54 on Friday. Rallybio Corporation has a 1 year low of $0.22 and a 1 year high of $1.24. The company has a market capitalization of $22.36 million, a PE ratio of -0.57 and a beta of -1.10. The company has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.43.

Rallybio (NASDAQ:RLYB) last announced its earnings results on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. The business had revenue of $0.21 million during the quarter. On average, research analysts expect that Rallybio Corporation will post -1.34 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on RLYB shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Rallybio in a research report on Wednesday, October 8th. Wall Street Zen lowered Rallybio from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Rallybio has a consensus rating of “Reduce” and an average price target of $5.00.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.